Tara Gomes

PhD, MHSc

Scientist

Biography

Tara Gomes is an epidemiologist and Principal Investigator of the Ontario Drug Policy Research Network (ODPRN), a provincial network of researchers with expertise in pharmaceutical utilization, outcomes and policy who rapidly conduct research for drug decision-makers in Ontario and across Canada.  She holds a Canada Research Chair in Drug Policy Research and Evaluation, is a Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital and ICES, and is an assistant professor at the University of Toronto.  Her research is focused on pharmacoepidemiology, drug safety and drug policy research leveraging large, administrative databases, and she has published over 200 peer-reviewed articles and over 100 policy reports in this area.  Dr. Gomes also works closely with government regulators at the provincial and national level to develop evidence to inform policies related to opioid use disorder and opioid-related harm through the Ontario Opioid Drug Observatory.  In 2014, she was awarded the Institute for Public Administration of Canada’s Bronze Public Sector Leadership Award in Health and Education to recognize the impact of the ODPRN’s work.

Recent Publications

  1. Little, DHW, Sutradhar, R, Cerasuolo, JO, Perez, R, Douketis, J, Holbrook, A et al.. Rates of rebleeding, thrombosis and mortality associated with resumption of anticoagulant therapy after anticoagulant-related bleeding. CMAJ. 2021;193 (9):E304-E309. doi: 10.1503/cmaj.201433. PubMed PMID:33649169 .
  2. Kaster, TS, Vigod, SN, Gomes, T, Wijeysundera, DN, Blumberger, DM, Sutradhar, R et al.. A practical overview and decision tool for analyzing recurrent events in mental illness: A review. J Psychiatr Res. 2021;137 :7-13. doi: 10.1016/j.jpsychires.2021.02.031. PubMed PMID:33636563 .
  3. Papadomanolakis-Pakis, N, Moore, KM, Peng, Y, Gomes, T. Prescription opioid characteristics at initiation for non-cancer pain and risk of treated opioid use disorder: A population-based study. Drug Alcohol Depend. 2021;221 :108601. doi: 10.1016/j.drugalcdep.2021.108601. PubMed PMID:33618194 .
  4. Camden, A, Ray, JG, To, T, Gomes, T, Bai, L, Guttmann, A et al.. Prevalence of Prenatal Opioid Exposure in Ontario, Canada, 2014-2019. JAMA Netw Open. 2021;4 (2):e2037388. doi: 10.1001/jamanetworkopen.2020.37388. PubMed PMID:33595660 PubMed Central PMC7890532.
  5. Antoniou, T, Pritlove, C, Shearer, D, Martins, D, Tadrous, M, Munro, C et al.. A qualitative study of a publicly funded pharmacy-dispensed naloxone program. Int J Drug Policy. 2021; :103146. doi: 10.1016/j.drugpo.2021.103146. PubMed PMID:33568317 .
  6. Fralick, M, Redelmeier, DA, Patorno, E, Franklin, JM, Razak, F, Gomes, T et al.. Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA. J Gen Intern Med. 2021; :. doi: 10.1007/s11606-020-06561-z. PubMed PMID:33564942 .
  7. Nichols, J, Mamdani, M, Gomes, T, Shah, BR, Casey, CG, Yu, CH et al.. Impact of Clinical Practice Guidelines on Blood Glucose Test Strip Prescription Rates in Manitoba and Saskatchewan (Canada): An Interrupted Time-Series Analysis. Can J Diabetes. 2020; :. doi: 10.1016/j.jcjd.2020.11.008. PubMed PMID:33558147 .
  8. Shakeri, A, Gomes, T, Suda, K, Tadrous, M. Choppy waters: The importance of accounting for shifting drug utilization during the COVID-19 pandemic in future observational drug-related studies. Basic Clin Pharmacol Toxicol. 2021; :. doi: 10.1111/bcpt.13568. PubMed PMID:33548160 .
  9. Chan, WV, Le, B, Lam, M, Shariff, SZ, Gomes, T, Lipscombe, L et al.. Opioid Prescribing Practices for Women Undergoing Elective Gynecologic Surgery. J Minim Invasive Gynecol. 2021; :. doi: 10.1016/j.jmig.2021.01.011. PubMed PMID:33503472 .
  10. Watt, JA, Campitelli, MA, Maxwell, CJ, Guan, J, Maclagan, LC, Gomes, T et al.. Fall-Related Hospitalizations in Nursing Home Residents Co-Prescribed a Cholinesterase Inhibitor and Beta-Blocker. J Am Geriatr Soc. 2020;68 (11):2516-2524. doi: 10.1111/jgs.16710. PubMed PMID:33460072 .
Search PubMed

Affiliations & Other Activities

  • Assistant Professor, Leslie Dan Faculty of Pharmacy, University of Toronto
  • Assistant Professor, Institute for Health Policy, Management and Evaluation, University of Toronto
  • Scientist, Institute for Clinical Evaluative Sciences
  • Principal Investigator, Ontario Drug Policy Research Network
X